Contraband (190178748)

  https://cordis.europa.eu/project/id/190178748

  Horizon Europe (2021-2027)

  ContraBand: the only heart failure medical device that is placed outside the heart

  EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOROPEN-01)

  cardiology

  2022-12-01 Start Date (YY-MM-DD)

  2024-11-30 End Date (YY-MM-DD)

  € 3,850,718

  Description

Worldwide 26 million people suffer from Congestive Heart Failure (CHF), a chronic condition that worsens with time and leads to staggering healthcare costs and a significant reduction of quality of life. ContraBand is an implantable device aiming to restore heart function in patient suffering from left ventricle failure. ContraBand’s benefits include built-in fail-safe for full reversibility of functionality, tremendous ease of use due to its proprietary stеnt-within-a-stеnt design and transcatheter delivery system, and full clinical flexibility to be compatible with pharmacotherapies and other CHF devices. In the project, we will finalise clinical development and introduce ContraBand into clinical routines in Europe. We expect to launch ContraBand in 2024, generate €15M in revenues in 2025 and €60M in 2026. Before market launch, we will create >95 jobs at the company in strategic locations in Europe.

  Complicit Organisations

1 Israeli organisation participates in Contraband.